Moderna and University of Oxford Begin Trials for Lynch Syndrome Vaccine
Moderna, in collaboration with the University of Oxford, has initiated human trials for a new mRNA-based vaccine aimed at treating Lynch syndrome, a genetic condition that significantly increases the risk of various cancers. The phase 1/2 INTERCEPT-Lynch trial will be conducted at Oxford University's clinical trial units, with the first patients expected to be dosed shortly. This trial marks a significant step as it could potentially be the first targeted treatment for Lynch syndrome, which affects approximately 1 in 400 people in England. The condition is characterized by genetic alterations that impair DNA repair, leading to a high risk of developing cancers such as colorectal, endometrial, and ovarian. Currently, treatment options are limited to surveillance, low-dose aspirin, and surgery. The vaccine, mRNA-4194, is designed to elicit immune responses against molecular targets associated with pre-cancerous cells, aiming to prevent cancer development.